These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

639 related articles for article (PubMed ID: 28395523)

  • 1. Adverse drug reactions reporting in Calabria (Southern Italy) in the four-year period 2011-2014: impact of a regional pharmacovigilance project in light of the new European Legislation.
    Leporini C; Marrazzo G; Mumoli L; Esposito S; Gallelli L; Mangano G; Brancati G; De Francesco EA; Russo E; De Sarro G;
    Expert Opin Drug Saf; 2017 May; 16(5):515-522. PubMed ID: 28395523
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of patient reporting of adverse drug reactions to the UK 'Yellow Card Scheme': literature review, descriptive and qualitative analyses, and questionnaire surveys.
    Avery AJ; Anderson C; Bond CM; Fortnum H; Gifford A; Hannaford PC; Hazell L; Krska J; Lee AJ; McLernon DJ; Murphy E; Shakir S; Watson MC
    Health Technol Assess; 2011 May; 15(20):1-234, iii-iv. PubMed ID: 21545758
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The impact of a changed legislation on reporting of adverse drug reactions in Sweden, with focus on nurses' reporting.
    Karlsson SA; Jacobsson I; Boman MD; Hakkarainen KM; Lövborg H; Hägg S; Jönsson AK
    Eur J Clin Pharmacol; 2015 May; 71(5):631-6. PubMed ID: 25845655
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Online reporting of adverse drug reactions: a study from a French regional pharmacovigilance center.
    Abadie D; Chebane L; Bert M; Durrieu G; Montastruc JL
    Therapie; 2014; 69(5):395-400. PubMed ID: 25269141
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacovigilance and drug safety 2011 in Calabria (Italy): Adverse events analysis.
    Scicchitano F; Giofrè C; Palleria C; Mazzitello C; Ciriaco M; Gallelli L; Paletta L; Marrazzo G; De Fazio S; Menniti M; Curia R; Arena C; Chimirri S; Patanè M; Esposito S; Cilurzo F; Staltari O; Russo E; De Sarro G
    J Res Med Sci; 2012 Sep; 17(9):872-5. PubMed ID: 23826016
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A survey of spontaneous reporting of adverse drug reactions in 10 years of activity in a pharmacovigilance centre in Portugal.
    Marques J; Ribeiro-Vaz I; Pereira AC; Polónia J
    Int J Pharm Pract; 2014 Aug; 22(4):275-82. PubMed ID: 24188533
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Signal detection activity on EudraVigilance data: analysis of the procedure and findings from an Italian Regional Centre for Pharmacovigilance.
    Monaco L; Melis M; Biagi C; Donati M; Sapigni E; Vaccheri A; Motola D
    Expert Opin Drug Saf; 2017 Mar; 16(3):271-275. PubMed ID: 28094583
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Strengthening and rationalizing pharmacovigilance in the EU: where is Europe heading to? A review of the new EU legislation on pharmacovigilance.
    Borg JJ; Aislaitner G; Pirozynski M; Mifsud S
    Drug Saf; 2011 Mar; 34(3):187-97. PubMed ID: 21332243
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ten years of pharmacovigilance in Italy: the experience of Emilia-Romagna region in the monitoring of drug's safety profile.
    Motola D; Melis M; Lo Bianco S; Buccellato E; Biagi C; Vaccheri A
    Expert Opin Drug Saf; 2014 Jul; 13(7):867-73. PubMed ID: 24809453
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The importance of monitoring adverse drug reactions in elderly patients: the results of a long-term pharmacovigilance programme.
    Carnovale C; Gentili M; Fortino I; Merlino L; Clementi E; Radice S; ViGer Group
    Expert Opin Drug Saf; 2016; 15(2):131-9. PubMed ID: 26882049
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Language does not come "in boxes": Assessing discrepancies between adverse drug reactions spontaneous reporting and MedDRA® codes in European Portuguese.
    Inácio P; Airaksinen M; Cavaco A
    Res Social Adm Pharm; 2015; 11(5):664-74. PubMed ID: 25596069
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patient Reporting in the EU: Analysis of EudraVigilance Data.
    Banovac M; Candore G; Slattery J; Houÿez F; Haerry D; Genov G; Arlett P
    Drug Saf; 2017 Jul; 40(7):629-645. PubMed ID: 28417320
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Are consumers ready to take part in the Pharmacovigilance System?--a Portuguese preliminary study concerning ADR reporting.
    Matos C; van Hunsel F; Joaquim J
    Eur J Clin Pharmacol; 2015 Jul; 71(7):883-90. PubMed ID: 26004569
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Under-reporting of adverse drug reactions, a problem that also involves medicines subject to additional monitoring. Preliminary data from a single-center experience on novel oral anticoagulants].
    Patrignani A; Palmieri G; Ciampani N; Moretti V; Mariani A; Racca L
    G Ital Cardiol (Rome); 2018 Jan; 19(1):54-61. PubMed ID: 29451510
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacovigilance and drug safety in Calabria (Italy): 2012 adverse events analysis.
    Giofrè C; Scicchitano F; Palleria C; Mazzitello C; Ciriaco M; Gallelli L; Paletta L; Marrazzo G; Leporini C; Ventrice P; Carbone C; Saullo F; Rende P; Menniti M; Mumoli L; Chimirri S; Patanè M; Esposito S; Cilurzo F; Staltari O; Russo E; De Sarro G;
    J Pharmacol Pharmacother; 2013 Dec; 4(Suppl 1):S55-60. PubMed ID: 24347984
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Direct reporting by patients of adverse drug reactions in Spain].
    Esther Salgueiro M; Jimeno FJ; Aguirre C; García M; Ordóñez L; Manso G
    Farm Hosp; 2013; 37(1):65-71. PubMed ID: 23461502
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FarmaREL: An Italian pharmacovigilance project to monitor and evaluate adverse drug reactions in haematologic patients.
    Fracchiolla NS; Artuso S; Cortelezzi A; Pelizzari AM; Tozzi P; Bonfichi M; Bocchio F; Gargantini L; De Rosa E; Vighi GD; Prestini L; Sammassimo S; Frungillo N; Pasquini MC; Ragazzi A; Boghi D; Pastore A; Lanzi E; Gritti G; Quaresmini G; Voltolini S; Gaiardoni R; Corti C; Vilardo MC; La Targia ML; Berini G; Magagnoli M; Bacci C; Consonni D; Rivolta AL; Muti G
    Hematol Oncol; 2018 Feb; 36(1):299-306. PubMed ID: 28771763
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Under-reporting of adverse drug reactions: a challenge for pharmacovigilance in India.
    Tandon VR; Mahajan V; Khajuria V; Gillani Z
    Indian J Pharmacol; 2015; 47(1):65-71. PubMed ID: 25821314
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adverse drug reactions reported to a provincial public health sector pharmacovigilance programme in South Africa.
    Jones J; Swart A; Tommy E; Cohen K; Stewart A; Voget J; Blockman M
    S Afr Med J; 2020 Nov; 110(12):1226-1230. PubMed ID: 33403970
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Geographical variation in reporting Interstitial Lung Disease as an adverse drug reaction: findings from an European Medicines Agency analysis of reports in EudraVigilance.
    Pinheiro L; Blake K; Januskiene J; Yue QY; Arlett P
    Pharmacoepidemiol Drug Saf; 2016 Jun; 25(6):705-12. PubMed ID: 27004571
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.